Health & Biotech
MGC Pharmaceuticals (ASX:MXC) is a global biopharma company focused on developing and supplying high-quality phytotherapeutics and phytomedicines to patients in Europe, Australasia, and North America. The company’s current phytomedicine range includes CannEpil, an orally-administered medical cannabis treatment for drug-resistant (or refractory) epilepsy, and CogniCann, a treatment to improve quality of life in dementia patients. Both products are certified as Investigational Medical Products in the EU, and emerge from MGC’s euGMP formulation facility.
MGC has a full seed to pharma operation, from proprietary genetics through to the final phytomedicines undergoing clinical trials and produced under the strictest manufacturing conditions in the world. Because of this full hold on the supply chain, MGC is also a supplier of multiple phytocannabinoid products, from genetics via seed or tissue culture , through cosmetics and nutraceuticals, all the way to final medications, and phytocannabinoid active pharmaceutical ingredients (API).
MGC has established licensed growing operations in the Czech Republic and Slovenia, a fully GMP certified resin extraction plant in Slovenia, and was the first company approval from the Maltese government to build a local medical cannabis cultivation and production facility.
KEY PEOPLE

Nativ Segev – Founder, Director
Nativ Segev has more than 10 years of experience in implementation, legislation and lobbying in the global medical cannabis industry, combined with over 15 years of experience in various executive roles. Previously, he served as CEO of a leading medical cannabis company with a large patient base.

Roby Zomer - Founder, Managing Director
Roby Zomer has 10 years’ experience in the biotech and agtech sectors and joined MGC Pharmaceuticals as executive director and CTO. He brings extensive business contacts and his scientific and engineering skillsets to ensure MGC’s position as a leader in research and development.

Brett Mitchell – Executive Chairman
Brett Mitchell is a corporate finance executive with over 20 years of experience in the finance and resources industries. He has been involved in the founding, financing and management of both private and publicly-listed resource companies and holds executive and non-executive directorship roles.

Dr. Jonathan Gruenfeld – Chief Scientific Officer
Certified in Israel, with clinical experience in at the M.D. Anderson Cancer Center, Dr. Grunfeld has spent the past twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cananabis as a treatment for oncological palliative care. He has directly been involved in the licensing and care of over 3000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology.
RELATED STOCKHEAD STORIES
Health & Biotech
MGC Pharma opens new production facility in Malta, now set to ramp up sales of CimetrA
Health & Biotech
ASX Health Stocks: Intelicare jumps 35pc on AI in-home sensor tech contract for seniors
Health & Biotech
With record growth in 2021, MGC Pharma’s Q1 trading update confirmed it’s laid the foundation for a global expansion
Health & Biotech
MGC Pharma lands milestone US$3 million CimetrA purchase order
Health & Biotech
MGC Pharma receives first order in the US, as it seeks to fast track commercialisation of CimetrA
Health & Biotech
Here’s why this fundie expects MGC Pharma’s stock price to more than double
Health & Biotech
MGC Pharma makes inroads in the fight against COVID-19, getting a regulatory nod in Germany and a successful trial in India
Health & Biotech
ASX Health Stocks: M&A winds blow as API gets an upgraded offer from Wesfarmers, jumps 15pc
Health & Biotech
Check Up: ASX biotech comes alive as health stocks tackle international markets
Health & Biotech
MGC Pharma share price soars after CannEpil+ scores UK-first import deal
Health & Biotech
ASX Health Stocks: Cannabis play Cronos scoots 19% higher on merger news, Telix gets FDA nod for clinical trial
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
News
Weed Week: Cannabis-infused drinks market could reach US$2.8 billion by 2025
News
ASX Small Cap Lunch Wrap: Who feels good after deworming today?
Health & Biotech
ASX Health Stocks: Neuroscientific pockets $25m R&D incentive, MGC Pharma jumps 15% on India approval for COVID-19 drug
Health & Biotech
MGC Pharma’s lead product CimetrA one step closer to a registered medicine for COVID-19 patients in India
News